Literature DB >> 2666638

Development of antiviral drugs for the treatment of AIDS: strategies and prospects.

W A Haseltine1.   

Abstract

This review makes it clear that there are numerous possibilities for the development of antiviral drugs for the treatment of AIDS. Drug design based on a profound understanding of specific enzymatic regulatory proteins and structural requirements for virus replication is possible. Information regulating these specific processes is increasing rapidly and will further speed preclinical drug design. Over time, this concerted effort to develop anti-AIDS drugs will radically alter the approach to the design of drugs for the treatment of other diseases.

Entities:  

Mesh：

Substances：

Year:  1989        PMID： 2666638

Source DB:  PubMed          Journal:  J Acquir Immune Defic Syndr (1988)        ISSN： 0894-9255


  12 in total

1.  Human immunodeficiency virus type 1 Pr55gag and Pr160gag-pol expressed from a simian virus 40 late replacement vector are efficiently processed and assembled into viruslike particles.

Authors:  A J Smith; M I Cho; M L Hammarskjöld; D Rekosh
Journal:  J Virol       Date:  1990-06       Impact factor: 5.103

2.  Generation of hybrid human immunodeficiency virus utilizing the cotransfection method and analysis of cellular tropism.

Authors:  A Velpandi; T Nagashunmugam; S Murthy; M Cartas; C Monken; A Srinivasan
Journal:  J Virol       Date:  1991-09       Impact factor: 5.103

3.  Generation and characterization of the human immunodeficiency virus type 1 mutants.

Authors:  A Adachi; N Ono; H Sakai; K Ogawa; R Shibata; T Kiyomasu; H Masuike; S Ueda
Journal:  Arch Virol       Date:  1991       Impact factor: 2.574

4.  High susceptibility of U937-derived subclones to human immunodeficiency virus type 1 infection correlates with accumulation of unintegrated circular viral DNA.

Authors:  M Kameoka; T Kimura; Y Okada; K Fujinaga; T Nakaya; H Takahashi; M Kishi; K Ikuta
Journal:  Virus Genes       Date:  1996       Impact factor: 2.332

5.  Integration is essential for efficient gene expression of human immunodeficiency virus type 1.

Authors:  H Sakai; M Kawamura; J Sakuragi; S Sakuragi; R Shibata; A Ishimoto; N Ono; S Ueda; A Adachi
Journal:  J Virol       Date:  1993-03       Impact factor: 5.103

Review 6.  Recent advances in the medical management of early HIV disease.

Authors:  P A Volberding
Journal:  J Gen Intern Med       Date:  1991 Jan-Feb       Impact factor: 5.128

7.  Oxathiin carboxanilide, a potent inhibitor of human immunodeficiency virus reproduction.

Authors:  J P Bader; J B McMahon; R J Schultz; V L Narayanan; J B Pierce; W A Harrison; O S Weislow; C F Midelfort; S F Stinson; M R Boyd
Journal:  Proc Natl Acad Sci U S A       Date:  1991-08-01       Impact factor: 11.205

Review 8.  Anti-AIDS drug development: challenges and strategies.

Authors:  P Mohan
Journal:  Pharm Res       Date:  1992-06       Impact factor: 4.200

9.  Mechanisms and structural determinants of HIV-1 coat protein, gp41-induced neurotoxicity.

Authors:  D C Adamson; K L Kopnisky; T M Dawson; V L Dawson
Journal:  J Neurosci       Date:  1999-01-01       Impact factor: 6.167

10.  Mutation in the primer binding site of the type 1 human immunodeficiency virus genome affects virus production and infectivity.

Authors:  T Nagashunmugam; A Velpandi; C S Goldsmith; S R Zaki; V S Kalyanaraman; A Srinivasan
Journal:  Proc Natl Acad Sci U S A       Date:  1992-05-01       Impact factor: 11.205
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.